Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Oct 16;12(10):1337. doi: 10.3390/biology12101337

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Sorafenib resistance gene set predicts the prognosis of AML patients: (a) Forest map shows the relationship between sorafenib resistance gene set and prognosis of patients. (b,c) The risk score distribution (b) and the survival outcome (SO) analysis (c) of the training cohorts (TC). (d) Heat map of 22 sorafenib resistance genes that are related to AML prognosis in TC. (e) The Kaplan–Meier survival curves of the high-risk (HR) and low-risk (LR) patients in the TC. (f) The time-dependent ROC analyses of the SF-res-22 prognosis model to estimate the 1-, 3-, and 5-year OS of TC patients. (g) PCA of 430 patients with Leucegene cohorts based on the composition of their cellular hierarchy and SF-res-7 (trained on PC1) captures the SF-res versus SF-sens axis. (h) Heat map of 7 genes that are significantly upregulated in the SF-res group. (i) Event-free survival and relapse-free survival of HR compared with LR patients, stratified by SF-res-7 score into SF-res-7 High (SF-res > SF-sens) and SF-res-7 Low (SF-sens > SF-res). Significance was evaluated through a log-rank test.